Webinar: Anti-GD2 immunotherapy: A Game Changer in High-Risk Neuroblastoma

Anti-GD2 Immunotherapy: A Game Changer in High-Risk Neuroblastoma

Livestream Webinar via Zoom

Date: September 3, 2025

Time: 1:00 PM EST (10:00 AM PST, 11:00 AM MST, 12:00 PM CST)

Presented by:

• Kristen L Dalton MSN RN CPNP-AC CPHON
• Linda D’Andrea, MSN, RN, PPCNP-BC, CPHON

Overview: This live webinar delves into the advanced use of anti-GD2 immunotherapies in the treatment of high-risk neuroblastoma. Participants will explore the purpose and pathophysiology of these therapies, supported by current literature. The session will distinguish between Dinutuximab and Naxitamab, focusing on their administration, timelines, and adverse event management. Additionally, nursing implications for patients receiving anti-GD2 therapies will be discussed, along with recent advances in administration and management, including institutional pathways, open protocols, and future directions. Finally, the coordination of care and resources necessary for successful anti-GD2 immunotherapy utilization will be addressed.

Learning Highlights:

• Advanced Use of Anti-GD2 Immunotherapies: Understand the purpose and pathophysiology of anti-GD2 therapies in treating high-risk neuroblastoma.
• Dinutuximab vs. Naxitamab: Learn the differences in administration, timelines, and adverse event management between these two therapies.
• Nursing Implications: Gain insights into the nursing implications for patients receiving anti-GD2 therapies.
• Recent Advances: Explore recent advances in administration and management, including institutional pathways, open protocols, and future directions.
• Coordination of Care: Learn about the coordination of care and resources necessary for successful anti-GD2 immunotherapy utilization.

Target Audience

This session is open to all registered nurses and allied health care providers.

Learner Outcome(s):

• Describe the purpose, pathophysiology, and literature supporting the use of anti-GD2 immunotherapies in high-risk neuroblastoma
• Distinguish the differences between Dinutuximab and Naxitamab, including: administration, timeline, and adverse event management.
• Discuss the nursing implications for patients receiving Anti-GD2 therapies
• Discuss the advances made in the administration and management of Anti-GD2 immunotherapies, including institutional pathways, open protocols, and future directions.
• Describe the coordination of care and resources needed for successful Anti-GD2 immunotherapy utilization. 

Continuing Education Credit

APHON will provide 1 nursing continuing professional development contact hour for successful completion of the webinar. Successful completion includes registration for the webinar session, attestation and attendance of the entire session, and completion of the post-webinar evaluation.

The Webinar and post-webinar evaluation is available for 30 days.

Association for Pediatric Hematology Oncology Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. Provider approved by the California Board of Registered Nursing, Provider Number 14513.

None of the planners for this activity have relevant financials relationship(s) to disclose with ineligible companies.